BRPI0911433A2 - imunoterapia específica de alérgeno mocusomal com administração dosada incial depois do início da estação de ano de pólen - Google Patents

imunoterapia específica de alérgeno mocusomal com administração dosada incial depois do início da estação de ano de pólen

Info

Publication number
BRPI0911433A2
BRPI0911433A2 BRPI0911433A BRPI0911433A BRPI0911433A2 BR PI0911433 A2 BRPI0911433 A2 BR PI0911433A2 BR PI0911433 A BRPI0911433 A BR PI0911433A BR PI0911433 A BRPI0911433 A BR PI0911433A BR PI0911433 A2 BRPI0911433 A2 BR PI0911433A2
Authority
BR
Brazil
Prior art keywords
mocusomal
specific immunotherapy
initial dosing
allergen specific
pollen season
Prior art date
Application number
BRPI0911433A
Other languages
English (en)
Portuguese (pt)
Inventor
Eike Gunther Wüstenberg
Eckhard-Carl Albrecht Puchert
Original Assignee
Alk Abelló As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39809974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911433(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alk Abelló As filed Critical Alk Abelló As
Publication of BRPI0911433A2 publication Critical patent/BRPI0911433A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0911433A 2008-04-11 2009-04-08 imunoterapia específica de alérgeno mocusomal com administração dosada incial depois do início da estação de ano de pólen BRPI0911433A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200800533 2008-04-11
PCT/EP2009/054186 WO2009124954A1 (en) 2008-04-11 2009-04-08 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Publications (1)

Publication Number Publication Date
BRPI0911433A2 true BRPI0911433A2 (pt) 2016-07-26

Family

ID=39809974

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911433A BRPI0911433A2 (pt) 2008-04-11 2009-04-08 imunoterapia específica de alérgeno mocusomal com administração dosada incial depois do início da estação de ano de pólen

Country Status (12)

Country Link
US (2) US9248097B2 (enExample)
EP (1) EP2265285B1 (enExample)
JP (2) JP5618981B2 (enExample)
CN (1) CN102014954A (enExample)
AU (1) AU2009235490B2 (enExample)
BR (1) BRPI0911433A2 (enExample)
CA (1) CA2720455A1 (enExample)
DE (1) DE202008006598U1 (enExample)
EA (1) EA019202B1 (enExample)
ES (1) ES2406391T3 (enExample)
MX (1) MX2010011012A (enExample)
WO (1) WO2009124954A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
EP2627354B1 (en) * 2010-10-15 2015-07-15 ALK-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
US20120100164A1 (en) 2010-10-15 2012-04-26 Alk-Abello A/S Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
WO2012148549A1 (en) 2011-02-25 2012-11-01 Benaroya Research Institute Detection of an immune response
JP2012240975A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
JP2012240978A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
SG10201605350UA (en) 2012-01-16 2016-08-30 Mckenna Elizabeth Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
KR102307248B1 (ko) 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
NZ630178A (en) 2012-09-07 2017-06-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2014047588A1 (en) 2012-09-21 2014-03-27 Elizabeth Mckenna Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR20160120735A (ko) 2014-02-28 2016-10-18 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
CA2967602C (en) 2014-11-14 2024-09-24 Regeneron Pharmaceuticals, Inc. METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
EP4344706A3 (en) 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CN120227453A (zh) 2018-05-13 2025-07-01 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
EP4513185A1 (en) * 2023-08-22 2025-02-26 Luxembourg Institute of Health (LIH) Early response biomarkers for allergen immunotherapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK137992D0 (da) 1992-11-13 1992-11-13 Alk Lab As Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof
JPH0959179A (ja) * 1995-08-28 1997-03-04 Japan Tobacco Inc スギ花粉症予防性を有する口腔衛生剤
DK1062341T3 (da) 1998-03-16 2008-11-03 Alk Abello As Muterede rekombinante allergener
FR2778244B1 (fr) 1998-04-30 2000-07-13 Univ Joseph Fourier Procede d'excitation d'une cavite optique pour la detection de gaz a l'etat de traces
DE60136653D1 (de) 2000-11-16 2009-01-02 Alk Abello As Mutante allergene
EP1504089A2 (en) 2002-05-16 2005-02-09 Alk Abell A/S Allergen mutants
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
WO2005077410A1 (en) 2004-02-06 2005-08-25 Greer Laboratories, Inc. Methods and compositions for dosing of allergens
BRPI0508078A (pt) * 2004-02-26 2007-07-17 Alk Abello As método para avaliar o potencial terapêutico de uma vacina para administração mucosa
US20060115499A1 (en) 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
JP5628473B2 (ja) 2004-11-10 2014-11-19 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ アレルギーワクチンの粘膜投与によるアレルギーの予防治療方法
DK1812059T3 (da) 2004-11-10 2010-09-13 Alk Abello As Fremgangsmåde til forebyggende behandling af allergi ved mukosaadministration af en allergivaccine
CN101098711A (zh) * 2005-01-07 2008-01-02 阿尔克-阿贝洛有限公司 通过口粘膜施用变态反应疫苗预防性治疗变态反应的方法
US20060210590A1 (en) * 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
EP1814516B1 (en) 2005-11-04 2012-12-26 Alk-Abelló A/S Use of a liquid allergy vaccine formulation for oromucosal administration
EP1974746B1 (en) * 2007-03-28 2012-01-11 Alk-Abelló A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration
DE202007004567U1 (de) 2007-03-28 2007-10-11 Alk-Abelló A/S Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung

Also Published As

Publication number Publication date
JP2011516521A (ja) 2011-05-26
CN102014954A (zh) 2011-04-13
EP2265285B1 (en) 2013-03-20
EA019202B1 (ru) 2014-01-30
US9248097B2 (en) 2016-02-02
DE202008006598U1 (de) 2008-10-02
WO2009124954A1 (en) 2009-10-15
JP2015013891A (ja) 2015-01-22
EP2265285A1 (en) 2010-12-29
CA2720455A1 (en) 2009-10-15
US20110142934A1 (en) 2011-06-16
US20140127298A1 (en) 2014-05-08
HK1147946A1 (en) 2011-08-26
ES2406391T3 (es) 2013-06-06
EA201071182A1 (ru) 2011-06-30
AU2009235490A1 (en) 2009-10-15
JP5618981B2 (ja) 2014-11-05
AU2009235490B2 (en) 2013-10-24
MX2010011012A (es) 2010-11-12

Similar Documents

Publication Publication Date Title
BRPI0911433A2 (pt) imunoterapia específica de alérgeno mocusomal com administração dosada incial depois do início da estação de ano de pólen
BRPI0918122A2 (pt) molécula de diaboy, diaboy, e mólecula dart
LT3216803T (lt) Stabilūs ir tirpūs antikūnai, slopinantys vegf
BRPI0917888A2 (pt) Formulação de anticorpo líquida estável
DK3072906T3 (da) Antistofformulering
EP2358392A4 (en) ANTIBODY FORMULATION
BRPI0912173A2 (pt) anticorpos anti-flt3
BRPI0913991A2 (pt) imunoterápicos da il6
EP2207803A4 (en) Cd9-specific human antibodies
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
BRPI0823297A2 (pt) Garrafa
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BRPI0912769A2 (pt) anticorpos anti-pirb
DK2342060T3 (da) Doseringsindretning
BRPI0919200A2 (pt) derivado de aminoácido
BRPI0908046A2 (pt) Aparelho aquecedor
AT10496U3 (de) Rollenprüfstand
TH91873B (th) ขวด
ITSS20080013A1 (it) Maxster junior
FI20080268A0 (fi) Vuorovaikutteinen järjestelmä
FI20080338A0 (fi) Lämmitin
FI8316U1 (fi) Annostin
UA17111S (uk) Дозуючий пристрій
ES1069109Y (es) Dispositivo clavador multiple de clavos
TH101572B (th) ถ้วย

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]